MedPath

Prevention of Preterm Birth With a Pessary in Singleton Gestations

Not Applicable
Completed
Conditions
Preterm Birth
Short Cervix
Interventions
Device: Bioteque cup pessary
Registration Number
NCT02056652
Lead Sponsor
University of Pennsylvania
Brief Summary

Preterm birth (PTB) is associated with over one million infant deaths annually worldwide. The incidence of PTB in the United States is 11.5% with more than 500,000 deliveries occurring at less than 37 weeks gestation annually. The rate of PTB in the United States increased to 12.8% in 2006, and remains high compared to almost all other developed countries, despite the introduction of many public health and medical interventions designed to delay PTB. Weekly treatment with 17-alpha hydroxyprogesterone caproate beginning at 16-20 weeks gestation has been shown to significantly reduce the risk of PTB and is currently recommended for women who experienced spontaneous PTB in a prior pregnancy. However, a strategy for the prevention of spontaneous PTBs in which therapeutic intervention is restricted to women with a previous PTB is likely to have a small effect on the overall rate of prematurity since only about 10% of spontaneous PTBs arise in women with such a history. A major reduction in rates of mortality and morbidity in premature babies will only be achieved with increased precision in the identification of women at risk of spontaneous PTB and through the development of an effective prevention for this complication. Transvaginal ultrasound measurement of cervical length is a reliable screening test for prediction of PTB. Although treatment with vaginal progesterone is effective in decreasing PTB in women with a short cervix, over 30% of women still experience premature delivery and many women find daily administration of progesterone to be challenging. Preliminary studies have suggested that use of an intravaginal pessary may be effective in preventing PTB. If effective this approach would be particularly appealing because of the wide availability of pessaries, ease of use, and low cost. Unfortunately, existing studies are inadequate to confirm effectiveness; a well designed, properly powered, prospective randomized trial is warranted prior to widespread implementation in clinical practice. We propose such a trial to study the effectiveness of the pessary in decreasing the incidence of PTB in an inner city Philadelphia population.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
122
Inclusion Criteria
  • 18-50 years of age
  • Singleton pregnancy (limits the participants to female gender)
  • Short cervical length (less than or equal to 25 mm) on second trimester ultrasound at 18-23 6/7 weeks gestation
Read More
Exclusion Criteria
  • Multiple gestation
  • Prior spontaneous preterm birth 16-36 6/7 weeks
  • Ruptured membranes
  • Lethal fetal structural anomaly
  • Fetal chromosomal abnormality
  • Cerclage in place (or planned placement)
  • Vaginal bleeding
  • Suspicion of chorioamnionitis
  • Ballooning of membranes outside the cervix into the vagina or CL = 0 mm on transvaginal ultrasound
  • Painful regular uterine contractions
  • Placenta previa
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PessaryBioteque cup pessaryUse of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
Primary Outcome Measures
NameTimeMethod
Number of Subjects Experiencing Preterm BirthBefore 37 weeks gestation (20 0/7 - 36 6/7 weeks)

Birth before 37 weeks gestation was captured.

Secondary Outcome Measures
NameTimeMethod
Number of Subjects Experiencing Neonatal DeathBetween birth and 28 days of age

Number of participants who experienced neonatal deaths from birth to day 28 was captured for each group.

Average Birth Weight of Babies Born on TrialTime of delivery

The birth weights of babies born in the pessary group was compared to those born in the no pessary group

Number of Subjects Experiencing ChorioamnionitisTime of delivery

The AE of Chorioamnionitis was captured for each group.

Number of Participants That Experienced Spontaneous Preterm Births on TrialBefore 37 weeks gestation

The number of spontaneous births that occurred in participants on trial before 37 weeks was captured.

Number of Participants Experiencing Spontaneous Rupture of MembranesLess than 34 weeks gestation

Rupture of membranes before 34 weeks gestation was captured in each group.

Trial Locations

Locations (4)

Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Geisinger Medical Center

🇺🇸

Danville, Pennsylvania, United States

Pennsylvania Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Thomas Jefferson University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath